The recent interest in beta-blockers as possible agents for drug repurposing in oncology
arises from many pre-clinical and epidemiologic studies suggesting a possible clinically
relevant antitumour effect. In lung cancer, given the contradictory results obtained, it is
crucial to further study its effects. A systematic review of the literature was planned to
evaluate a possible beneficial effect of beta-blocker on overall survival in lung cancer
patients. Medline and Embase databases were searched from inception until 1 May 2018 to …